Cell Biophysics

, Volume 21, Issue 1–3, pp 93–107 | Cite as

Radiolabeled octreotide

What lessons for antibody-mediated targeting?
  • S. J. Mather
  • E. Ur
  • J. Bomanji
  • D. Ellison
  • G. M. Besser
  • K. E. Britton
Article

Abstract

Octreotide is a synthetic analog of the peptide hormone somatostatin (SMS). A wide variety of tumors express enhanced numbers of SMS receptors, notably neuroendocrine tumors and lymphomas, but also some of the more common adenocarcinomas. Octreotide contains only eight amino acids, some of which are in the (D) configuration in order to enhance the stability of the molecule in vivo. Tyrosine and ATPA-containing analogs of octreotide have been synthesized and labeled with iodine-123 and indium-111, respectively, with the intention of targeting SMS receptor-containing tumors for diagnostic purposes. Both radiopharmaceuticals demonstrate a high sensitivity and specificity for these tumors, indicating a clinical role for these agents in management of these diseases.

Lessons can be learned from the success of these agents when designing improved antibody-based molecules. Tumor uptake of radiolabeled octreotide is very rapid, occurring within minutes of administration. Blood clearance is also rapid, such that tumors are soon visible even in areas of high blood background. An interesting finding has been the differences between the pharmacokinetics of the iodinated and indium-labeled species. Although the majority of123I-Tyr3-octreotide undergoes hepatobiliary excretion,111In-DTPAPhe1-octreotide is eliminated predominantly by the kidneys. These results suggest that the smallest possible antibody-like tracers are likely to have advantages over native immunoglobulins and conventionals Fab-like fragments.

Index Entries

Octreotide somatostatin 1In 123I 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wass, J. A. H. (1989) Somatostatin,in Endocrinology (DeGroot, Leslie J., ed.), W. B. Saunders, London.Google Scholar
  2. 2.
    Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., Marbach, P., Petcher, T. J., and Pless, J. (1982) SMS-201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.Life. Sci. 31, 1133–1140.PubMedCrossRefGoogle Scholar
  3. 3.
    Krenning, E. P., Bakker, W. H., Breeman, W. A. P., Koper, J. W., Jooij, P. P. M., Ausema, L., Lameris, J. S., Reubi, J. C., and Lamberts, S. W. J. (1989) Localisation of endocrines related tumours with radioiodinated analogue of somatostatin.Lancet i, 242–245.CrossRefGoogle Scholar
  4. 4.
    Bomanj, J., Ur, E., Mather, S. J., Ellison, D., Moyes, J., Grossman, A., Britton, K. E., and Besser, G. M. (1992) A sintigraphic comparison of 123-I meta-iodobenzylguanidine (MIBG) and an 123-I labeled somatostatin analogue (Tyr-3-octreotide) in metastatic carcinoid tumours.J. Nucl. Med. 33, 1121–1124.Google Scholar
  5. 5.
    Bakker, W. H., Krenning, E. P., Wout, A., Breeman, W. A. P., Koper, J. W., Jooij, P. P. M., Reubi, J. C., Klijn, J. G., Visser, T. J., Docter, R., and Lamberts, S. W. J. (1990) Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabelling, purification, biologic activity and in-vivo application in animals.J. Nucl. Med. 31, 1501–1509.PubMedGoogle Scholar
  6. 6.
    Bakker, W. H., Albert, R., Bruns, C., Breeman, W. A. P., Hofland, L. J., Marbach, P., Pless, J., Pralet, D., Stoltz, B., Koper, J. W., Lamberts, S. W. J., Visser, T. J., and Krenning, E. P. (1991) [111In-DTPA-d-Phe1]-Octreotide a potential radiopharmaceutical for imaging of somatostatin receptorpositive tumours: synthesis, radiolabelling and in-vitro validation.Life Sci. 49, 1583–1591.PubMedCrossRefGoogle Scholar
  7. 7.
    Reubi, J. C., Kvols, L., Krenning, E., and Lamberts, S. W. (1991) In vitro and in vivo detection of somatostatin receptors in human malignant tissues.Acta. Oncol. 30, 463–468.PubMedCrossRefGoogle Scholar
  8. 8.
    Ur, E., Mather, S. J., Bomanj, J., Ellison, D., Britton, K. E., Wass, J. A. H., Grossman, A., and Besser, G. M. (1992) Pituitary imaging using a labelled somatostatin analogue in acromegaly.Clinical Endocrinology 36, 147–150.PubMedGoogle Scholar
  9. 9.
    Durbin, H., Milligan, E. M., Mather, S. J., Tucker, D. F., Raymond, R., and Bodmer, W. F. (1988) Monoclonal antibodies to placental alkaline phosphatase: preclinical evaluation in a human xenograft tumor model of F(ab′)2 and Fab fragments.Int. J. Cancer 2(Suppl.), 59–66.CrossRefGoogle Scholar
  10. 10.
    Winter, G. and Milstein, C. (1991) Man-made antibodies.Nature 349, 293–299.PubMedCrossRefGoogle Scholar
  11. 11.
    Reubi, J. C., Perin, M., Rivier, J., and Vale, W. (1982) High affinity binding sites for somatostatin to rat pituitary.Biochem. Biophys. Res. Comm. 105, 1538–1545.PubMedCrossRefGoogle Scholar
  12. 12.
    Glockshuber, R., Malia, M., Pfizinger, I., and Pluckthun, A. (1990) A comparison of strategies to stabilise immunoglobulin Fv-fragments.Biochemistry 19, 1362–1366.CrossRefGoogle Scholar
  13. 13.
    Ward, E. S., Gussow, D., Griffiths, A. D., Jones, P. T., and Winter, G. (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted fromE. Coli.Nature 341, 544–546.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 1993

Authors and Affiliations

  • S. J. Mather
    • 1
  • E. Ur
    • 1
  • J. Bomanji
    • 1
  • D. Ellison
    • 1
  • G. M. Besser
    • 1
  • K. E. Britton
    • 1
  1. 1.Departments of Nuclear Medicine and EndocrinologySt. Bartholomews HospitalLondon

Personalised recommendations